ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



The Role of Pentraxin-3 and Angiopoietin-1in the Inflammation Pathway in Chronic Kidney Disease Pentraxin-3 ,Angiopoietin-1 and CKD

Murat Cihan, Ahmet Karatas, Ebru Canakci.



Abstract
Download PDF Cited by 0 ArticlesPost

Introduction and Aim: Angiopoetin-1 and Pentraxin-3 are new generation biomarkers in the inflammation pathway that have been studied in CKD and other inflammatory diseases. This study aims to investigate the relationship of Pentraxin-3 and Angiopoetin-1 in the inflammation pathway in chronic kidney disease (CKD).
Materials and Methods: Our study was planned single-center, prospective, cross-sectional study. This study includes 25 healthy volunteers, 29 predialysis cases, 34 cases in routine hemodialysis program.Blood was drawn after 12 hours of fasting. In addition to routine biochemical tests, Pentraxin-3 Angiopoetin-1, 1,25 hydroxy Vitamin D levels were measured. Age and gender parameters, BUN, creatinine, e-GFR values of the cases were recorded.
Results: Pentraxin-3 levels were not statistically significant for all three groups (p=0.993).For angiopoietin-1 levels, statistical significance was found between all three groups (p

Key words: Chronic Kidney Damage, Inflammation, Pentraxin-3, Angiopoietin-1







Bibliomed Article Statistics

20
17
29
19
24
44
30
21
21
19
21
23
R
E
A
D
S

7

15

9

10

10

22

13

8

9

10

10

6
D
O
W
N
L
O
A
D
S
010203040506070809101112
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.